Dragonfly Therapeutics

Dragonfly Therapeutics is a company based in Waltham, United States. It was launched in 2016 by Tyler Jacks, founding Director of MIT's Koch Institute, together with tech entrepreneur Bill Haney and UC Berkeley scientist David Raulet. The company's mission is to revolutionize disease treatment by inventing therapies that harness the body's immune system for vastly improved patient outcomes. Dragonfly builds drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation and beyond, and has built a broad pipeline of novel B & T cell depleters addressing critical autoimmune targets. In collaboration with AbbVie, BMS, and Gilead, its platform has generated drug candidates to target challenging diseases in a variety of therapeutic areas.

Dragonfly was launched in 2016 by Tyler Jacks, founding Director of MIT's Koch Institute, together with longtime friend and tech entrepreneur Bill Haney, and UC Berkeley scientist David Raulet. Their shared goal is harnessing the power of the immune system to provide breakthrough treatments for patients. The company's mission is to revolutionize disease treatment by inventing therapies that harness the body's immune system for vastly improved patient outcomes. Dragonfly has built a broad pipeline of novel B & T cell depleters addressing critical autoimmune targets for diseases with high unmet need. In collaboration with AbbVie, BMS, and Gilead, its platform has generated drug candidates to target challenging diseases in a variety of therapeutic areas. In addition to a set of advanced programs in the clinic or handed off to pharma partners, Dragonfly is developing novel immune engagers in a range of fields, including autoimmune and inflammatory diseases, fibrosis and oncology.

Harnesses the power of the immune system to fight disease; builds drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation and beyond.

1. 1Home | Dragonflydragonflytx.com
2. 2About | Dragonflydragonflytx.com
3. 3Dragonfly Therapeutics (United States)wikidata.org